Pipeline · Bill → Law
Step 1
Introduced
Jan 30, 2023
Step 2
Referred
Jan 30, 2023
the Judiciary
Step 3
Committee
Feb 9, 2023
Reported out
Step 4
Senate
Jul 11, 2024
Passed Senate w/ Changes
Step 5
House floor
Moves to House
Step 6
Resolve Changes
Step 7
Signed
SummaryCRS Summary
This bill limits in certain instances the number of patents that a reference biological product manufacturer can assert in a patent infringement lawsuit against a company seeking to sell a biosimilar version. Specifically, if the biosimilar manufacturer completes certain actions as part of an abbreviated pathway to get market approval, the bill limits, subject to exceptions and waivers, the number of certain types of patents that the reference product manufacturer may assert, such as patents filed more than four years after the reference product received market approval.
Timeline · 10 actions
Jul 15, 2024
Received in the House.
Jul 15, 2024
Held at the desk.
Jul 12, 2024
Message on Senate action sent to the House.
Jul 11, 2024
Measure laid before Senate by unanimous consent.
Jul 11, 2024
Passed Senate with an amendment by Unanimous Consent.
Mar 1, 2023
Committee on the Judiciary. Reported by Senator Durbin without amendment. Without written report.
Mar 1, 2023
Placed on Senate Legislative Calendar under General Orders. Calendar No. 22.
Feb 9, 2023
Committee on the Judiciary. Ordered to be reported without amendment favorably.
Jan 30, 2023
Introduced in Senate
Jan 30, 2023
Read twice and referred to the Committee on the Judiciary.